Evidence statements

Level of evidenceEvidence statement
Level 1-The evidence suggests ziprasidone (i/m) is safe for use in rapid tranquillisation, however its effectiveness with highly agitated service users is not known.
Level 2The relative effectiveness and safety of (i/m) ziprasidone compared to (i/m) haloperidol as an agent for rapid tranquillisation cannot be established on the basis of this evidence.

From: 7, Methods and findings

Cover of Violence
Violence: The Short-Term Management of Disturbed/Violent Behaviour in In-Patient Psychiatric Settings and Emergency Departments.
NICE Clinical Guidelines, No. 25.
National Collaborating Centre for Nursing and Supportive Care (UK).
Copyright © 2006, Royal College of Nursing.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means electronic,mechanical, photocopying, recording or otherwise,without prior permission of the Publishers or a licence permitting restricted copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1T 4LP. This publication may not be lent, resold, hired out or otherwise disposed of by ways of trade in any form of binding or cover other than that in which it is published,without the prior consent of the Publishers.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.